7.84
-0.71 (-8.30%)
| Penutupan Terdahulu | 8.55 |
| Buka | 8.84 |
| Jumlah Dagangan | 1,047,029 |
| Purata Dagangan (3B) | 370,986 |
| Modal Pasaran | 380,931,488 |
| Harga / Jualan (P/S) | 8.11 |
| Harga / Buku (P/B) | 3.06 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -6.04 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -100.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.29% |
| Nisbah Semasa (MRQ) | 13.93 |
| Aliran Tunai Operasi (OCF TTM) | -59.79 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.41 M |
| Pulangan Atas Aset (ROA TTM) | -33.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -68.14% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Artiva Biotherapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -3.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.80 |
|
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.99% |
| % Dimiliki oleh Institusi | 89.73% |
| Julat 52 Minggu | ||
| Median | 18.00 (129.59%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 11 Mar 2026 | 18.00 (129.59%) | Beli | 7.13 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10.60 | - | 6,510,416 | 69,010,410 |
| Jumlah Keseluruhan Kuantiti Bersih | 6,510,416 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 69,010,410 | |||
| Purata Pembelian Keseluruhan ($) | 10.60 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Pengarah | 11 May 2026 | Beli (+) | 6,510,416 | 10.60 | 69,010,410 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |